Today’s TransMission is a SNiP of one of our favorite papers featuring Label IT®. Nasri and Mir et al. describe an elegant use for Label IT® in enriching CRISPR/Cas-edited cells. For use in the clinic, it is highly desirable to limit the number of nonedited cells that may compete with the therapeutic, modified cells. Read on to learn how Label IT® was used to enhance the CRISPR genome-editing workflow!
“United we stand, divided we… small?”
CRISPR prime editing, introduced in 2019, harnesses a Frankensteinian enzyme–a Cas nickase fused to a reverse transcriptase–to perform gene edits with putatively higher fidelity than traditional CRISPR/Cas genome editing systems. In this SNiP, we highlight recent work from Grünewald et al. that shows the prime editor fusion can be split without negative consequence to editing, suggesting that the nickase and reverse transcriptase modules operate in trans. This finding is a boon for delivery and use of prime editing machinery with space-constrained vectors, such as AAV and lentiviral vectors.
Read on to learn more about prime editing and the authors’ discovery.
Proper storage and handling of TransIT® reagents are required to maintain optimal transfection performance. This is a quick reference page for storage and handling of Mirus TransIT® Transfection Reagents and Kits.